Loading patent…
AssigneeThe Regents of the University of Michigan
InventorsDavid Ginsburg, Gallia Levy, Han-Mou Tsai
Estimating the term…
The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
A composition comprising recombinant ADAMTS13 polypeptide that is at least 95% identical to SEQ ID NO:2 from amino acid position 75 to amino acid position 1427 having von Willebrand factor (VWF) cleaving protease activity wherein said composition is free of proteins found in human plasma other than said recombinant ADAMTS13 polypeptide.
A pharmaceutical composition comprising recombinant ADAMTS 13 polypeptide that is at least 95% identical to SEQ ID NO:2 from amino acid position 75 to amino acid position 1427 having yon Willebrand factor (VWF) cleaving protease activity, wherein said composition is free of proteins found in human plasma other than said recombinant ADAMTS 13 , and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.